Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Authors :: Rothenberg, Marc E.
Klion, Amy D.
Roufosse, Florence E.
Kahn, Jean Emmanuel
Weller, Peter Fahey
Simon, Hans-Uwe
Schwartz, Lawrence B.
Rosenwasser, Lanny J.
Ring, Johannes
Griffin, Elaine F.
Haig, Ann E.
Frewer, Paul I.H.
Parkin, Jacqueline M.
Gleich, Gerald J.
Source :: Rothenberg, Marc E., Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter F. Weller, Hans-Uwe Simon, Lawrence B. Schwartz, et al. 2008. “Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab.” New England Journal of Medicine 358 (12) (March 20): 1215–1228. doi:10.1056/nejmoa070812.
Publication Year :: 2008
Publisher :: New England Journal of Medicine (NEJM/MMS), 2008.
Abstract: The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.

Language :: English
ISSN :: 00284793
Database :: Digital Access to Scholarship at Harvard (DASH)
Journal :: Rothenberg, Marc E., Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter F. Weller, Hans-Uwe Simon, Lawrence B. Schwartz, et al. 2008. “Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab.” New England Journal of Medicine 358 (12) (March 20): 1215–1228. doi:10.1056/nejmoa070812.
Publication Type :: Academic Journal
Accession number :: edshld.1.28702415
Document Type :: Journal Article
Full Text :: https://doi.org/10.1056/NEJMoa070812